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LETTER TO THE EDITOR

A National Study of the
Provision of Oncofertility
Services to Female
Patients in Canada
To the Editor:
I applaud Yee and co-investigators1 for bringing attention
to the thousands of Canadian women “severely underserved” regarding fertility preservation prior to cancer
treatment, and particularly for their recommendation
6 encouraging all provinces to “implement a provincial
strategy to increase the affordability of fertility preservation
services to cancer patients through public health funding.”
This recommendation would allow all “reproductive age”
cancer patients, rather than just the financially advantaged,
to access fertility preservation strategies.
Currently in Canada, public funding of fertility preservation
for women with cancer exists only in Quebec, which is not
surprising as Quebec is the only province that publicly
funds medically indicated IVF for treatment of subfertility.2
For the other provinces (and territories) to comply with
recommendation 6 of Yee and colleagues,1 the politicians
would have to consider a sequence of questions they would
rather not consider:
•• If fertility preservation prior to chemotherapy for
cancer patients is worthy of public funding, ought not
fertility preservation prior to chemotherapy for women
with autoimmune or other medical conditions also be
publicly funded?
•• If fertility preservation for cancer patients is worthy
of public funding, ought not in vitro fertilization of
the oocytes so preserved and the intrauterine transfer
of the embryos created after intracytoplasmic sperm
injection also be publicly funded?
•• If in vitro fertilization for all women who have
survived cancer is worthy of public funding, ought
not in vitro fertilization for other etiologies of oocyte
depletion, and indeed other etiologies of subfertility,
also be publicly funded?
The provinces and territories are well aware of the
implications of this sequence of questions. In fact an
action is currently before The Human Rights Tribunal
of Ontario, arguing discrimination against women with
oocyte depletion seeking IVF, as public funding for IVF

exists in Ontario exclusively for the etiology of completely
blocked fallopian tubes.3 If this action prevails, it would be
difficult for Ontario not to extend public funding to other
medically recognized etiologies of infertility.
An important group of “severely under-served” female
cancer patients in Canada that did not receive focus in
the study of Yee and co-investigators1 is children younger
than reproductive age. The overall survival for pediatric
malignancies is more than 80%.4 Although the informed
choice process for children is more complex,5 requiring
the participation of parents or other substitute decisionmakers, children with socioeconomically less advantaged
parents should not be discriminated against with respect
to having the same access to fertility preservation and the
ability to have a child as the children of financially betteroff parents.
The logical way for provinces (and territories) to comply
with recommendation 6 is to follow Quebec’s lead and
implement “public health funding” for fertility preservation
of women with cancer. The logical way for provinces
(and territories) to act on the logic of the sequence of
questions posed in this letter would be to follow Quebec’s
lead and finally catch up with the rest of the developed
world (outside the United States), and implement public
funding for fertility promotion and treatment strategies for
all medical indications as part of Canadian health care.5
Jeff Nisker, MD, PhD, FRCSC
Department of Obstetrics and Gynaecology, Schulich School
of Medicine and Dentistry, Western University, London ON
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